RxDoctor Payments Data

Amadeo Abraham, MD

Pulmonary Disease · Louisville, KYNPI 1891959441

Payments from drug & device makers

$504in general payments, 2019–2025

Across 35 payments — averaging $14.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$159
  • Novartis$64
  • Genentech USA, Inc.$53
  • Mylan Specialty L.p.$46
  • Actelion Pharmaceuticals US, Inc.$40
  • Regeneron Healthcare Solutions, Inc.$34
  • plus $108 from 7 others

What the payments were for

  • Food & beverage$46692%
  • Education$388%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$504 in reported general payments places this provider in the 15th percentile of 226 pulmonary disease providers in Kentucky.

See all pulmonary disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$180,075
Medicare patients
475
Services billed
1,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab151$562,233
XolairOmalizumab90$323,742
Trelegy ElliptaFluticasone/Umeclidin/Vilanter361$287,698
Aralast NpAlpha-1-Proteinase Inhibitor11$127,888
Prolastin CAlpha-1-Proteinase Inhibitor12$98,653
Spiriva RespimatTiotropium Bromide86$68,542
Breztri AerosphereBudesonide/Glycopyr/Formoterol71$50,567
Breo ElliptaFluticasone/Vilanterol79$39,244
SymbicortBudesonide/Formoterol Fumarate86$29,124
Incruse ElliptaUmeclidinium Bromide54$18,189
EliquisApixaban15$15,683
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate59$10,102
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$9,518
Advair HfaFluticasone Propion/Salmeterol16$6,595
Ventolin HfaAlbuterol Sulfate91$6,462

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$159$345,131494 claims
Grifols USA, LLCProlastin C$25$98,65312 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$13$78,059100 claims
MerckDulera$17$5,66317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 226 pulmonary disease providers in Kentucky.

Other pulmonary disease in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →